Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Clinuvel Pharmaceuticals ( (AU:CUV) ) has provided an update.
Clinuvel Pharmaceuticals presented new case studies at the European Academy of Dermatology and Venereology conference, demonstrating the efficacy of SCENESSE® in treating vitiligo. The studies showed significant and stable repigmentation in patients, with no unexpected safety concerns, marking a potential breakthrough for those with extensive vitiligo and offering hope for effective long-term treatment.
The most recent analyst rating on (AU:CUV) stock is a Buy with a A$13.50 price target. To see the full list of analyst forecasts on Clinuvel Pharmaceuticals stock, see the AU:CUV Stock Forecast page.
More about Clinuvel Pharmaceuticals
Clinuvel Pharmaceuticals operates in the biotechnology industry, focusing on developing treatments for skin disorders. Its primary product, SCENESSE®, is used for conditions like vitiligo and erythropoietic protoporphyria, with a market focus on dermatological therapies.
Average Trading Volume: 129,629
Technical Sentiment Signal: Sell
Current Market Cap: A$593.5M
For detailed information about CUV stock, go to TipRanks’ Stock Analysis page.